Literature DB >> 26733303

Role of HDACs in optic nerve damage-induced nuclear atrophy of retinal ganglion cells.

Heather M Schmitt1, Cassandra L Schlamp1, Robert W Nickells2.   

Abstract

Optic neuropathies are characterized by retinal ganglion cell (RGC) death, resulting in the loss of vision. In glaucoma, the most common optic neuropathy, RGC death is initiated by axonal damage, and can be modeled by inducing acute axonal trauma through procedures such as optic nerve crush (ONC) or optic nerve axotomy. One of the early events of RGC death is nuclear atrophy, and is comprised of RGC-specific gene silencing, histone deacetylation, heterochromatin formation, and nuclear shrinkage. These early events appear to be principally regulated by epigenetic mechanisms involving histone deacetylation. Class I histone deacetylases HDACs 1, 2, and 3 are known to play important roles in the process of early nuclear atrophy in RGCs, and studies using both inhibitors and genetic ablation of Hdacs also reveal a critical role in the cell death process. Select inhibitors, such as those being developed for cancer therapy, may also provide a viable secondary treatment option for optic neuropathies.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Apoptosis; Glaucoma; Heterochromatin; Histone deacetylase (HDAC); Neurodegeneration; Nuclear atrophy; Optic nerve injury; Retinal ganglion cell

Mesh:

Substances:

Year:  2015        PMID: 26733303      PMCID: PMC5125391          DOI: 10.1016/j.neulet.2015.12.012

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  42 in total

1.  Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms.

Authors:  Takuma Uo; Timothy D Veenstra; Richard S Morrison
Journal:  J Neurosci       Date:  2009-03-04       Impact factor: 6.167

Review 2.  Unravelling heterochromatin: competition between positive and negative factors regulates accessibility.

Authors:  Niall Dillon; Richard Festenstein
Journal:  Trends Genet       Date:  2002-05       Impact factor: 11.639

Review 3.  HDAC inhibitors and neurodegeneration: at the edge between protection and damage.

Authors:  Karen C Dietz; Patrizia Casaccia
Journal:  Pharmacol Res       Date:  2010-02-01       Impact factor: 7.658

4.  Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells.

Authors:  Julia Biermann; Jennifer Boyle; Amelie Pielen; Wolf Alexander Lagrèze
Journal:  Mol Vis       Date:  2011-02-05       Impact factor: 2.367

5.  Nuclear atrophy of retinal ganglion cells precedes the bax-dependent stage of apoptosis.

Authors:  Katherine T Janssen; Caitlin E Mac Nair; Joel A Dietz; Cassandra L Schlamp; Robert W Nickells
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-11       Impact factor: 4.799

6.  Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes.

Authors:  Zhibin Wang; Chongzhi Zang; Kairong Cui; Dustin E Schones; Artem Barski; Weiqun Peng; Keji Zhao
Journal:  Cell       Date:  2009-08-20       Impact factor: 41.582

Review 7.  Mouse models of retinal ganglion cell death and glaucoma.

Authors:  Stuart J McKinnon; Cassandra L Schlamp; Robert W Nickells
Journal:  Exp Eye Res       Date:  2008-12-07       Impact factor: 3.467

8.  Inhibition of HDAC2 protects the retina from ischemic injury.

Authors:  Jie Fan; Oday Alsarraf; Mohammad Dahrouj; Kenneth A Platt; C James Chou; Dennis S Rice; Craig E Crosson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-12       Impact factor: 4.799

9.  Divergent evolution of human p53 binding sites: cell cycle versus apoptosis.

Authors:  Monica M Horvath; Xuting Wang; Michael A Resnick; Douglas A Bell
Journal:  PLoS Genet       Date:  2007-06-15       Impact factor: 5.917

Review 10.  Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.

Authors:  J F Kerr; A H Wyllie; A R Currie
Journal:  Br J Cancer       Date:  1972-08       Impact factor: 7.640

View more
  13 in total

1.  Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo.

Authors:  Annabelle Schlüter; Bahar Aksan; Rossella Fioravanti; Sergio Valente; Antonello Mai; Daniela Mauceri
Journal:  Mol Neurobiol       Date:  2019-06-03       Impact factor: 5.590

2.  The effect of metalloprotein inhibitors on cellular metal ion content and distribution.

Authors:  Yao Chen; Barry Lai; Zhenjie Zhang; Seth M Cohen
Journal:  Metallomics       Date:  2017-03-22       Impact factor: 4.526

3.  Quantification and image-derived phenotyping of retinal ganglion cell nuclei in the nee mouse model of congenital glaucoma.

Authors:  Carly J van der Heide; Kacie J Meyer; Adam Hedberg-Buenz; Danielle Pellack; Nicholas Pomernackas; Hannah E Mercer; Michael G Anderson
Journal:  Exp Eye Res       Date:  2021-09-29       Impact factor: 3.467

4.  Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

Authors:  Dahea You; Jason R Richardson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2020-03-19       Impact factor: 3.922

Review 5.  Neuroprotection for glaucoma: Requirements for clinical translation.

Authors:  Leonard A Levin; Megan E Crowe; Harry A Quigley
Journal:  Exp Eye Res       Date:  2016-12-09       Impact factor: 3.467

6.  BAX-Depleted Retinal Ganglion Cells Survive and Become Quiescent Following Optic Nerve Damage.

Authors:  Ryan J Donahue; Margaret E Maes; Joshua A Grosser; Robert W Nickells
Journal:  Mol Neurobiol       Date:  2019-10-31       Impact factor: 5.590

7.  AAV2-Mediated Transduction of the Mouse Retina After Optic Nerve Injury.

Authors:  Robert W Nickells; Heather M Schmitt; Margaret E Maes; Cassandra L Schlamp
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-12-01       Impact factor: 4.799

Review 8.  Glaucoma as a Metabolic Optic Neuropathy: Making the Case for Nicotinamide Treatment in Glaucoma.

Authors:  Pete A Williams; Jeffrey M Harder; Simon W M John
Journal:  J Glaucoma       Date:  2017-12       Impact factor: 2.503

Review 9.  Molecular regulation of neuroinflammation in glaucoma: Current knowledge and the ongoing search for new treatment targets.

Authors:  Gülgün Tezel
Journal:  Prog Retin Eye Res       Date:  2021-08-01       Impact factor: 21.198

10.  Integrated microarray analysis provided novel insights to the pathogenesis of glaucoma.

Authors:  Jinhui Wang; Daofei Qu; Jinghong An; Guoming Yuan; Yufu Liu
Journal:  Mol Med Rep       Date:  2017-10-04       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.